This invention relates to an improved method for the preparation of highly or substantially pure Indigotindisulfonate sodium (1). It further relates to the novel crystalline form I of Indigotindisulfonate sodium (1) and the process for its preparation.

The present invention relates to a method for detecting renal disease and for assessing the efficacy of dialysis treatment using imaging agents having desirable in vivo properties.

A process for the preparation of substantially pure Indocyanine green of formula with purity greater than 99.0% is provided. More particularly, the embodiments relate to the process for the preparation of Indocyanine green of formula and its intermediates thereof. It further provides crystalline form I of Indocyanine green of formula and process thereof.

The invention provides a process for preparing N,N-di(3,5-dimethylphenyl)perylene bis(dicarboximide), and other pigments having modified properties, by reaction of perylene-3,4,9,10-tetracarboxylic dianhydride with 3,5-dimethylaniline, or a mixture of 3,5-dimethyl aniline and at least one other primary amine, in the presence of a secondary amine or tertiary amine as catalyst, wherein the reaction occurs in an aqueous reaction medium and in the presence of added seed crystals of N,N-di(3,5-dimethylphenyl) perylenebis(dicarboximide), such that the aqueous medium is present at the beginning of the reaction.

The object of the invention is a process for the isolation and culture of strains, the strains, use thereof, media for culturing thereof and a form of scytonemin.

The present invention relates to an improved process for preparation of Indigo carmine of Formula (I), in high purity, more than 99.5%.

Described herein are photonic crystals comprising a plurality of substantially uniform zein particles. The photonic crystals can be fabricated by assembling the plurality of substantially uniform zein particles into one or more ordered and periodic structures that generate structural color. Also described herein are methods of using the photonic crystals described herein, e.g., as colorants in consumer products, such as food, drugs and/or cosmetics.

Disclosed herein are receptor-substrate complexes comprising an octacationic tricyclic cyclophane and a pyrrole dye complexed therein and methods of using and making the same.

Disclosed herein is a tricyclic octacationic cyclophane and complexes comprising the tricyclic octacationic cyclophane and a perylene diimide dye complexed therein and methods of using and making the cyclophane and complexes.

A C.I. Pigment Yellow 101 has an average particle size of 100 nm or more and 700 nm or less, and, in an X-ray diffraction pattern obtained by powder X-ray diffractometry, a second peak from a low angle side is present at a diffraction angle 2 in the range of 11.66 or more and 11.86 or less.